Known as the blockbuster brand name anticancer therapy Avastin, Bevacizumab recently captured a positive opinion from the EU for its success in treating cervical cancer. On March 2, 2015 Roche Pharmaceuticals announced that the European Union’s (EU) Committee for Medicinal Products for Human Use expressed a positive opinion of Bevacizumab when used alongside standard chemotherapy[…]
Positive Opinion from the EU for Bevacizumab as Cervical Cancer Treatment
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, Monoclonal Antibodies / mAb Tags: BevacizumabPaclitaxel Mar 19, 2015
Pancreatic Cancer Predicted to Become the Second Cause of U.S. Cancer Deaths
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: EGFRPaclitaxel Jun 19, 2014
Startling news emerged on May 19, 2014 with an ominous report issued from the Pancreatic Cancer Action Network. The report has predicted that pancreatic cancer will become the #2 cause of cancer deaths in the year 2030, bumping colorectal cancer to the third slot. This sobering information comes in response to recent changes in American[…]
FDA Gives New Indication for Paclitaxel
Chemotherapeutic / Anti-Neoplastic, New Indication Approval, OTC and Compounding Product, TEVA API Tags: Paclitaxel Sep 12, 2013
On September 6, 2013 the FDA approved a new indication for the formidable pancreatic cancer drug Paclitaxel. Known as the brand name Abraxane, which is marketed by Celgene, Paclitaxel is now officially indicated for the first-line treatment of patients with metastatic pancreatic cancer. Paclitaxel will be used in a combination treatment, alongside Gemcitabine, to treat[…]
Elacridar – A Unique Delivery System Fighting Chemotherapy Resistance
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: cancer treatmentchemotherapyDocetaxelimatinibIrinotecanPaclitaxel Jun 03, 2011
Elacridar, an ABCB1 modulator acting as a drug transporter, has been proven to have beneficial effects on the resistance of cancer cells to standard chemotherapeutic agents. This unique delivery system makes resistant cancers more susceptible to standard chemotherapeutic regimen. A study done by Ho Lun Wong et al showed beneficial results when Elacridar was used[…]
